Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

SMPL

MAY 26, 2020

CBD industry will be worth $16 billion by 2025. In the absence of oversight, the push to get more patients access to cannabis medicine — and bona fide CBD — has been co-opted by a push to make as much money as possible off the next big wellness fad. “At fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

OCTOBER 17, 2019

billion in 2025, according to Grandview Research. Another researcher, New Frontier Data, pegged the global value of legal and illicit cannabis together at $340 billion in 2018. They don’t want to disallow access to the only thing that may stop epileptic seizures in children or is part of a patient’s treatment plan.”

Law 40

Law Seed-To-Sale Hemp Recreational 40